YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	28.43M 9.41M 8.11M 7.63M 6.95M 13.08M 893M 13.15M 90.23M 35.12M 454M 35.32M 34.55M 1.51B	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	28.55M 9.44M 8.15M 7.66M 6.98M 13.13M 896M 13.2M 90.59M 35.26M 456M 35.46M 34.69M 1.51B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.18%	Yield 2024 *	-	Yield 2025	-

Aug. 30	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
May. 03	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 02	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
Nov. 12	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
25-09-10	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
24-09-01	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-11	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
24-03-27	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-26	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
23-08-31	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-03-26	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21-08-09	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

21-02-26	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
21-01-18	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
21-01-18	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
20-12-15	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
20-11-19	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	2022-03-30
Oren Attiya DFI	Director of Finance/CFO	45	-
Daniel Shapira AUD	Comptroller/Controller/Auditor	72	2019-06-25

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	2021-12-08
Shimon Bar-Kama BRD	Director/Board Member	74	2018-12-03
Varda Kalal BRD	Director/Board Member	58	2022-02-13

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation : Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases : Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors : Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	9.41M
MITSUBISHI ESTATE CO., LTD.	-1.77%	-0.26%	+17.50%	+94.79%	28.87B
EMAAR PROPERTIES	-1.48%	-2.91%	-25.31%	+49.79%	26.04B
MITSUI FUDOSAN CO., LTD.	-2.57%	-0.33%	-4.24%	+36.16%	26.14B
ALPHA DHABI HOLDING	-3.20%	-5.32%	-33.61%	-63.51%	20.44B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-2.74%	-2.88%	+7.13%	+67.05%	19.58B
DLF LIMITED	-0.24%	+0.16%	-10.76%	+31.07%	17.61B
HONGKONG LAND HOLDINGS LIMITED	+1.50%	-0.85%	+27.87%	+129.38%	17.11B
ALDAR PROPERTIES	-1.18%	-3.58%	-20.44%	+43.26%	16.38B
AZRIELI GROUP LTD.	+0.15%	+1.24%	+27.97%	+95.78%	16B
Average	-1.87%	-0.47%	-1.54%	+53.75%	20.91B
Weighted average by Cap.	-1.40%	-0.19%	-2.19%	+53.12%

	2024	2025
Net sales	76K 25.14K 21.69K 20.4K 18.59K 34.95K 2.39M 35.14K 241K 93.87K 1.21M 94.4K 92.35K 4.02M	-
Net income	-3.68M -1.22M -1.05M -986K -899K -1.69M -115M -1.7M -11.66M -4.54M -58.69M -4.56M -4.47M -195M	-3M -991K -855K -804K -733K -1.38M -94.06M -1.39M -9.51M -3.7M -47.85M -3.72M -3.64M -159M
Net Debt	980K 324K 280K 263K 240K 451K 30.77M 453K 3.11M 1.21M 15.65M 1.22M 1.19M 51.9M	115K 38.04K 32.82K 30.87K 28.12K 52.88K 3.61M 53.17K 365K 142K 1.84M 143K 140K 6.09M